The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells. 1985

M Okabe, and K Gomi, and M Morimoto, and N Nakamizo

Highly purified recombinant human interferon-gamma produced by Escherichia coli (ReIFN-gamma) was examined for ability to stimulate natural killer (NK) cell cytotoxic activity and antibody-dependent cell-mediated cytotoxicity in human peripheral blood lymphocytes (PBLs) in comparison with natural human interferon-gamma (IFN-gamma) and with recombinant human interferon-beta produced by E. coli (ReIFN-beta). The activity of ReIFN-gamma to stimulate NK cell cytotoxicity was about 10 times greater than that of ReIFN-beta and similar to that of IFN-gamma when PBLs were pretreated with each interferon for 16 hr. The effects of ReIFN-gamma were completely neutralized by a rabbit anti-ReIFN-gamma antibody, but not by a rabbit anti-ReIFN-beta. ReIFN-gamma did not show any significant NK-enhancing effect when it was added directly to the killing phase of standard 51Cr-release assay for 4 hr, while ReIFN-beta showed a marked effect. The time course study showed that the NK-activating effect of ReIFN-gamma was not expressed until 2 hr after the start of incubation, while that of ReIFN-beta was expressed rapidly and sufficiently within 15 min. This kinetic difference between ReIFN-gamma and ReIFN-beta was confirmed by an experiment using the Ca2+-pulse method, in which the killing rate in the Ca2+-dependent stage of NK cytolysis was increased by ReIFN-gamma, but only after 6 hr of preincubation, while the effect by ReIFN-beta was expressed rapidly at 30 min. These findings suggest that ReIFN-gamma and ReIFN-beta may stimulate NK cell cytotoxicity through different intracellular events after they bind to their receptors on the surface of NK cells.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D011995 Recombination, Genetic Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. Genetic Recombination,Recombination,Genetic Recombinations,Recombinations,Recombinations, Genetic
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell

Related Publications

M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
March 1983, Biochemical and biophysical research communications,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
January 1984, Journal of interferon research,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
January 2019, iScience,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
March 2001, European journal of immunology,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
July 1985, Journal of immunology (Baltimore, Md. : 1950),
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
March 1998, Proceedings of the National Academy of Sciences of the United States of America,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
February 1982, Cellular immunology,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
August 1996, Clinical and experimental immunology,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
May 1999, Transplantation proceedings,
M Okabe, and K Gomi, and M Morimoto, and N Nakamizo
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!